Drugs · Brain health technique
Anti-Tau Therapies (Monoclonal Antibodies)
Evidence grade: Experimental

Emerging biologics that target pathological tau aggregates to slow neurofibrillary tangle propagation. Agents under study include semorinemab (Genentech), gosuranemab (Biogen), tilavonemab (AbbVie), and BIIB076.
- Practice
- Drugs
- Principle
- Treatment
- Tactic
- Emerging Longevity / Neuroregenerative Agents
- Evidence grade
- Experimental
- Strength of evidence
- Low
How to practice Anti-Tau Therapies (Monoclonal Antibodies)
Access limited to research protocols for early Alzheimer’s or tauopathies. Requires tau PET or CSF confirmation and frequent infusions with imaging follow-up. Not approved for clinical use; future trials will clarify efficacy. Participation appropriate for biomarker-confirmed early disease in specialized research centers.
The evidence behind Anti-Tau Therapies (Monoclonal Antibodies)
Anti-tau antibodies are experimental lab-made immune proteins that bind tau outside cells. The antibodies aim to block tau's spread and slow tangle buildup. Early trials show good safety, and biomarker tests show the drugs engage tau. Evidence is early, though the biological case is strong.
Impact on brain health
Tau buildup tracks with memory and thinking decline more directly than amyloid does. That makes tau buildup a key treatment target. Trials so far show minimal improvement in memory and thinking.
Reviewed by BetterBrain's clinical advisors · Updated November 2026 · Our science
More Drugs techniques
Pair this with other habits from the same practice.

Evidence grade: Context Dependent
Anti-Amyloid Monoclonal Antibodies
FDA-approved biologic drugs that target beta-amyloid plaques to slow Alzheimer’s progression, including lecanemab (Leqembi®), donanemab (Kisunla™).

Evidence grade: Context Dependent
Antihypertensives
Medications that lower blood pressure to protect vascular and brain health, including ACE inhibitors (lisinopril, enalapril), ARBs (losartan, valsartan), calcium channel blockers…

Evidence grade: Context Dependent
GLP-1 Receptor Agonists
A class of injectable or oral medications that mimic the hormone glucagon-like peptide-1 (GLP-1) to improve insulin sensitivity, suppress appetite, and reduce inflammation.
Take control of your brain health
BetterBrain gives you a personalized protocol of techniques like these, backed by science and tailored to you.